ライフサイエンスコーパス: pfu

1 xposed to aerosolized monkeypox virus (10(5) PFU).

2 nuates mouse neuroinvasiveness (>/=1,000,000 PFU).

3 : wild-type mice, 10 PFU; CD1(-/-) mice, 1.6 PFU).

4 ted (1 received 100 PFU, and 2 received 1000 PFU).

5 PFU, 3 received 100 PFU, and 3 received 1000 PFU).

6 during pregnancy with wild-type GPCMV (10(5) PFU).

7 eroconverted (the seroconverter received 100 PFU).

8 AST mice, whereas BALB/c mice survived 10(6) PFU.

9 persisted up to day 180 for doses >/=3 x 105 PFU.

10 ge at a median protective dose (PD50) of 2.4 PFU.

11 4 x 10(5) PFU; (NA+HA)(Min), >/=3.16 x 10(6) PFU.

12 of 800-2200 PFU and a detection limit of 600 PFU.

13 ven after intracerebral inoculation of 10(3) PFU.

14 e PKR(-/-) mice succumbed at a dose of 10(8) PFU.

15 ring in animals infected with 10(6) or 10(7) pfu.

16 intraperitoneal route, with an LD(50) of 14 PFU.

17 est African clade yielded an LD(50) of 7,600 PFU.

18 ted elevated ratios of virion DNA copies per PFU.

19 which reached, respectively, 0.005 and 0.017 PFU.

20 able dose of 50 PFU and a lethal dose of 500 PFU.

21 than 50% of participants at doses >/=3 x 105 PFU.

22 ainst RSV challenge at doses as low as 10(3) PFU.

23 ose vaccinated with 3 million or 100 million PFU.

24 doses of EBOV (</=100 plaque-forming units [PFU]).

25 ting Bacteroides GB-124 (mean = 4.36 log(10) PFU/100 mL) and that GB-124 phages, HAdV, and NoV were a

26 centrations of 1.71 x 10(2) and 4.27 x 10(2) PFU/100 mL, respectively, higher than nonhost specific R

27 tly reduced specific infectivity (si) (WT, 1 PFU/118 particles vs. P2(Min), 1 PFU/35,000 particles),

28 BOV vaccine (3 million plaque-forming units [PFU], 20 million PFU, or 100 million PFU) or placebo.

29 Vax-WN02 3.7- x -10(5) plaque-forming units (PFU), 3.7 x 10(4) PFU, 3.7 x 10(3) PFU, or placebo.

30 a 4, 7 subjects seroconverted (1 received 10 PFU, 3 received 100 PFU, and 3 received 1000 PFU).

31 0(5) plaque-forming units (PFU), 3.7 x 10(4) PFU, 3.7 x 10(3) PFU, or placebo.

32 (si) (WT, 1 PFU/118 particles vs. P2(Min), 1 PFU/35,000 particles), a phenotype that will be discusse

33 paratuberculosis cells ranging from 1 to 110 PFU/50 ml of milk and 6 to 41,111 PFU/g of feces were in

34 vaccinees (22%) receiving 10(7) or 5 x 10(7) pfu, 56 participants were given a lower dose (3 x 10(5)

35 oses ranging from 1.0 x 10(3) to 1.0 x 10(5) PFU administered subcutaneously (s.c.).

36 e upper and lower airways by 3.8 log10 total PFU and 2.7 log10 PFU/g of tissue, respectively, compare

37 d to quantitate VSV in the range of 800-2200 PFU and a detection limit of 600 PFU.

38 cted with 2 inocula: a survivable dose of 50 PFU and a lethal dose of 500 PFU.

39 re frequent at high vaccine doses (9 x 10(6) PFU and greater).

40 illion and 100 million plaque-forming units (PFU) and homologous VSV-Ebola vaccine boost in healthy a

41 nd wild-type cPKCalpha (Ad WTPKCalpha, 10(7) pfu), and proliferation was measured.

42 negative nPKCepsilon (Ad DNPKCepsilon, 10(4) pfu), and wild-type cPKCalpha (Ad WTPKCalpha, 10(7) pfu)

43 2, 3 subjects seroconverted (1 received 100 PFU, and 2 received 1000 PFU).

44 converted (1 received 10 PFU, 3 received 100 PFU, and 3 received 1000 PFU).

45 llion or 100 million PFU than with 3 million PFU, and these correlated strongly with neutralization t

46 ase (Ad-Cre; 2 x 10(7) plaque forming units [PFU]) and adeno-associated viral vectors expressing VEGF

47 irus serotype 2 (strain 16 681) at 1 x 10(7) PFU/animal.

48 crRNAs from the 7 shared CRISPR loci in Pfu are processed for use by all 3 effector complexes, a

49 FU than in the group that received 3 million PFU, as assessed by ELISA and by pseudovirion neutraliza

50 Surprisingly, animals exposed to 10 PFU by either route showed no signs of disease.

51 edian mosquito-inoculated dose of WNV (10(5) PFU) by needle.

52 (50% lethal dose titers: wild-type mice, 10 PFU; CD1(-/-) mice, 1.6 PFU).

53 ched, with loss of most infectious virus (<5 PFU/cell) by 20 to 24 h p.i.

54 .i.]) after maximal virus titers (150 to 200 PFU/cell) have been reached, with loss of most infectiou

55 ing infection at low multiplicity (MOI = 0.1 PFU/cell) inhibited HCMV in a dose-dependent manner and

56 a low multiplicity of infection (MOI; 0.0001 PFU/cell) or with 2009 pandemic H1N1 viruses at a high M

57 2009 pandemic H1N1 viruses at a high MOI (10 PFU/cell).

58 (viability: control, 33.02+/-1.09%; LacZ 10 pfu/cell, 32.85+/-1.51%; catalase 1 pfu/cell, 62.09+/-4.

59 LacZ 10 pfu/cell, 32.85+/-1.51%; catalase 1 pfu/cell, 62.09+/-4.17%*; catalase 2 pfu/cell, 98.71+/-3

60 alase 1 pfu/cell, 62.09+/-4.17%*; catalase 2 pfu/cell, 98.71+/-3.35%*; catalase 10 pfu/cell, 99.68+/-

61 lase 2 pfu/cell, 98.71+/-3.35%*; catalase 10 pfu/cell, 99.68+/-1.99%*; *p<0.05 vs. control; mean+/-SE

62 ime of intranasal (10(6) PFU) or i.p. (10(7) PFU) challenge with virus resulted in complete protectio

63 cient to ensure <8 Phi6 plaque-forming unit (PFU)/cm(2) in all tests.

64 The Pfu Cmr complex cleaves complementary target RNAs, and C

65 challenging the animals with 10(5) or 10(6) PFU Congo Basin MPXV 30 days postvaccination and evaluat

66 s, we evaluated cellular responses and viral PFU counts in murine RAW264.7 cells and primary macropha

67 Virus was eluted from the swabs and PFU determined by titration on human A549 cells, accordi

68 we evolved a version of Pyrococcus furiosus (Pfu) DNA polymerase that tolerates modification of the g

69 ology 3 domain binds directly to the central PFU domain of Doa1.

70 Our data suggest that the PUL and PFU domains of Doa1 promote the formation of a Doa1-Cdc4

71 ant-negative cPKCalpha (Ad DNPKCalpha, 10(4) pfu), dominant-negative nPKCepsilon (Ad DNPKCepsilon, 10

72 At the 2 x 10(7) PFU dose (used in phase 3 trials), the most common local

73 ty and immunogenicity profile of the 2 x 107 PFU dose in adults and support consideration of lower do

74 On day 28 at the 2 x 10(7) PFU dose, the geometric mean IgG ELISA endpoint titre wa

75 y results support selection of the 2 x 10(7) PFU dose.

76 x 10(3), 3 x 10(4), 3 x 10(5), or 3 x 10(6) PFU doses of rVSVG-ZEBOV-GP or placebo.

77 x 10(6), 9 x 10(6), 2 x 10(7), or 1 x 10(8) PFU doses of rVSVG-ZEBOV-GP or placebo.

78 At 3 x 10(5) pfu, early-onset reactogenicity remained frequent (45 [8

79 form of PKCalpha (Ad-myr-PKCalpha, 1 x 10(7) pfu), EGF (10(-7) M), or both.

80 affected the severity of disease, with 10(4) pfu eliciting milder keratitis after delayed onset compa

81 , mice were ocularly infected with 2 x 10(4) PFU/eye of virulent HSV-1 strain McKrae.

82 A viral inoculum of 10(5) pfu/eye was determined to be optimal for use in further

83 ritoneal dose of vaccinia virus (VACV) was 3 PFU for CAST mice, whereas BALB/c mice survived 10(6) PF

84 The detection threshold was 0.017 PFU for DENV-1, 0.004 PFU for DENV-2, 0.8 PFU for DENV-3

85 on threshold was 0.017 PFU for DENV-1, 0.004 PFU for DENV-2, 0.8 PFU for DENV-3, and 0.7 PFU for DENV

86 17 PFU for DENV-1, 0.004 PFU for DENV-2, 0.8 PFU for DENV-3, and 0.7 PFU for DENV-4.

87 PFU for DENV-2, 0.8 PFU for DENV-3, and 0.7 PFU for DENV-4.

88 evaluation of the vaccine dose of 20 million PFU for preexposure prophylaxis and suggest that a secon

89 y sensitive, detecting H5 virus levels of <1 PFU from each of the HA clades.

90 m 1 to 110 PFU/50 ml of milk and 6 to 41,111 PFU/g of feces were indicated by the PMS-phage assay.

91 airways by 3.8 log10 total PFU and 2.7 log10 PFU/g of tissue, respectively, compared to those in unva

92 With an intermediate dose of 2 x 10(3) PFU, genomic diversity present in nasal lavage samples i

93 r LD50 values: PR8, 32 plaque-forming units (PFU); HA(Min), 1.7 x 10(3) PFU; NA(Min), 2.4 x 10(5) PFU

94 Pyrococcus furiosus (Pfu) harbors three CRISPR-Cas immune systems: a Cst (Typ

95 With a high dose of 2 x 10(6) PFU, however, reassortment levels were high (avg. 59%) a

96 x 103, 3 x 104, 3 x 105, 3 x 106, or 2 x 107 PFU in 115 adults and a dose of 2 x 107 PFU in 20 adoles

97 107 PFU in 115 adults and a dose of 2 x 107 PFU in 20 adolescents and 20 children.

98 d, at best, provided a visual read of 10-100 pfu in a 100-microL sample when a colorimetric substrate

99 e when used at 2 x 107 plaque-forming units (PFU) in a trial in Guinea.

100 se of 10, 100, or 1000 plaque-forming units (PFU) in cohorts of 3.

101 with sensitivity of 5 plaque-forming units (PFU) in less than 40 min.

102 ved with high challenge dosages (1.0 x 10(4) PFU) in the rat lethal disease model.

103 strain) was measured by plaque-forming unit (PFU) inhibition.

104 -dose (2 x 10(8) PFU) or low-dose (1 x 10(7) PFU) intramuscular immunization of rhesus macaques.

105 d to vaccination with a high dose (2,000,000 PFU), intranasal inoculation with a low dose (200 PFU) r

106 of gestation with virulent RVFV (1.0 x 10(6) PFU intravenously).

107 ations of MS2 and Phi6 were approximately 20 PFU L(-1) and approximately 0.1 PFU L(-1), respectively,

108 oximately 20 PFU L(-1) and approximately 0.1 PFU L(-1), respectively, in the chambers enclosing the a

109 nt the binding sites of Pyrococcus furiosus (Pfu) L7Ae on its cognate RNase P RNA (RPR).

110 wabs with different concentrations of ZIKAV (PFU/microL).

111 med by the limit of detection (as low as 0.1 PFU/microL, equivalent to copy number of 4.9) in spiked

112 respectively, for the aeration basin and 79 PFU min(-1) and 0.3 PFU min(-1) for the sewer pipes.

113 ding emission rates of MS2 and Phi6 were 547 PFU min(-1) and 3.8 PFU min(-1), respectively, for the a

114 he aeration basin and 79 PFU min(-1) and 0.3 PFU min(-1) for the sewer pipes.

115 of MS2 and Phi6 were 547 PFU min(-1) and 3.8 PFU min(-1), respectively, for the aeration basin and 79

116 U mL(-)(1)), giving detection limit of 0.230 PFU mL(-)(1) and 0.710 PFU mL(-)(1) respectively.

117 ection limit of 0.230 PFU mL(-)(1) and 0.710 PFU mL(-)(1) respectively.

118 and dengue 3 viruses in plaque forming unit (PFU mL(-)(1)), giving detection limit of 0.230 PFU mL(-)

119 reporter phage concentration of 1.76 x 10(2) pfu ml(-1) are capable of detecting approximately 5 CFU

120 s achieved within 9 hours using 9.23 x 10(3) pfu ml(-1) of phage in selective culture enrichments of

121 n a linear range from 5 x 10(4) to 5 x 10(6) PFU mL(-1) with a detection limit of 10(4) PFU mL(-1).

122 of 3-45 plaque-forming units per milliliter (pfu mL(-1)) with detection limit of 0.04 pfu mL(-1), com

123 f 10(7) plaque-forming units per milliliter (PFU mL(-1)), were not detected in air after flushing.

124 er (pfu mL(-1)) with detection limit of 0.04 pfu mL(-1), comparable to state-of-the-art polymerase ch

125 ) PFU mL(-1) with a detection limit of 10(4) PFU mL(-1).

126 EBOV and SUDV were 465 plaque-forming units (PFU)/mL (1010 copies/mL) and 324 PFU/mL (8204 copies/mL)

127 etection of less than 1 plaque forming unit (pfu)/mL in a direct EIS assay.

128 lectric signal up to 10 Plaque forming unit (PFU)/mL with a limit of detection (LOD) of 8.75 PFU/mL.

129 ming units (PFU)/mL (1010 copies/mL) and 324 PFU/mL (8204 copies/mL), respectively.

130 D) of the dual-channel PSPWB for S-OIV is 30 PFU/mL (PFU, plaque-forming unit), which was calculated

131 ects and allowed low limits of detection (12 pfu/mL and 39 pfu/mL in buffer and in river water, respe

132 lent sensitivity and limit of detection (9.3 pfu/mL and 9.8 pfu/mL in buffer and in river water, resp

133 ent specificity, a limit of detection of 0.2 pfu/mL and a dynamic range of thirteen orders of magnitu

134 15 min with reasonable sensitivity of 10(7) pfu/mL and minimal sample preparation, making this trans

135 ed low limits of detection (12 pfu/mL and 39 pfu/mL in buffer and in river water, respectively) that

136 y and limit of detection (9.3 pfu/mL and 9.8 pfu/mL in buffer and in river water, respectively) were

137 mmunosensor showed a limit of detection of 6 pfu/mL in buffer, allowing the detection of MS2 to level

138 ured S-OIV at a concentration of 1.8 x 10(2) PFU/mL in mimic solution, which contained PBS-diluted no

139 OD for S-OIV in PBS was determined to be 3.5 PFU/mL in this experiment.

140 ntrations, followed by incubation with 10(3) PFU/ml of D29 mycobacteriophage for 24 h and then real-t

141 ed peak viremia titers of 2.8 to 3.1 log(10) PFU/ml on day 2 or 4 after infection, but there was no d

142 accine groups given doses of 10(6.6)-10(7.2) pfu/mL than for those given doses of 10(7.6)-10(8.2) pfu

143 detection range was determined to be from 10 PFU/mL to 5000 PFU/mL with an R(2) value greater than 0.

144 was determined to be from 10 PFU/mL to 5000 PFU/mL with an R(2) value greater than 0.9.

145 e recombinant RVs grew to high titer (>10(7) PFU/ml) and remained genetically stable during serial pa

146 cate rapidly and to high titer (up to 10(10) PFU/ml) in mosquito cells, producing extensive cytopathi

147 rVSVDeltaG*/BDVG produced high titers (10(7) PFU/ml) of cell-free virus progeny, but this virus exhib

148 High (>10(7) PFU/ml) viral loads were detected in all major organs (l

149 ained high virulence (MLD50, up to 0.5 log10 PFU/mL) within 5 passages.

150 restored release of infectious virus (>10(6) PFU/ml), confirming that SKI-1/S1P processing is require

151 razide and hydroxyl diothiolated linkers (15 pfu/mL).

152 phage particles ranging from 10(2) to 10(6) pfu/mL.

153 saline (PBS) over a range of 18-1.8 x 10(6) PFU/mL.

154 recombinant virus reaches titers of >/=10(4) pfu/mL.

155 han for those given doses of 10(7.6)-10(8.2) pfu/mL.

156 n ability for DENV detection as low as 10(4) PFU/mL.

157 )/mL with a limit of detection (LOD) of 8.75 PFU/mL.

158 fer were inoculated intranasally with 10,000 PFU/mouse influenza A/WSN/33 (H1N1) virus.

159 tely expressed and purified fragments, split Pfu mutant behaves identically to wild-type DNA polymera

160 ad received 1 x10(7) pfu (n=35) or 5 x 10(7) pfu (n=16) of rVSV-ZEBOV (high-dose vaccinees) or placeb

161 with 59 volunteers who had received 1 x10(7) pfu (n=35) or 5 x 10(7) pfu (n=16) of rVSV-ZEBOV (high-d

162 igh-dose lot of rVSVDeltaG-ZEBOV-GP (1 x 108 pfu, n = 264; high-dose group), or placebo (n = 133).

163 ticipants were given a lower dose (3 x 10(5) pfu, n=51) or placebo (n=5) to assess the effect of dose

164 taG- ZEBOV-GP (2 x 107 plaque-forming units [pfu], n = 797; combined-lots group), a single high-dose

165 ue-forming units (PFU); HA(Min), 1.7 x 10(3) PFU; NA(Min), 2.4 x 10(5) PFU; (NA+HA)(Min), >/=3.16 x 1

166 (Min), 1.7 x 10(3) PFU; NA(Min), 2.4 x 10(5) PFU; (NA+HA)(Min), >/=3.16 x 10(6) PFU.

167 n the absence of hormone pretreatment, 2,000 PFU of a clinical isolate of HSV-2 was sufficient to est

168 ed groups of swine with a control Ad5, 10(8) PFU of Ad5-pIFN-alpha, low- or high-dose Ad5-pIFN-gamma,

169 at pigs treated with 10(8), 10(9), or 10(10) PFU of Ad5-poIRF7/3(5D) 24 h before FMDV challenge were

170 re detectable in 1 subject (who received 100 PFU of chimera 4).

171 was evaluated following inoculation of 10(7) PFU of Delta145 or parental virus into guinea pigs immun

172 guinea pigs twice with either 10(5) or 10(6) PFU of Delta145, establishing pregnancy, and challenging

173 laque-forming units (PFU) of DENV-1 or 10(5) PFU of DENV-3.

174 tly challenged 19 weeks later with 1 x 10(5) PFU of DENV2.

175 rotein and challenged the macaques with 1000 pfu of EBOV.

176 e protected against challenge with 2 x 10(7) PFU of homologous HPAIV.

177 mice were injected in one AC with 3 x 10(4) PFU of HSV-1 (KOS) in a volume of 2 microL.

178 n infected immediately thereafter with 10(4) PFU of HSV-1 strain 17syn+.

179 Following corneal infection with 2 x 10(6) PFU of HSV-1 strain McKrae, 50% of wild-type mice surviv

180 ell culture, and swine inoculated with 10(9) PFU of human adenovirus type 5 expressing porcine IFN-al

181 10(5) T cells prior to challenge with 10(4) PFU of IHD-J-Luc and treated with BCV postchallenge surv

182 organs, and survived rechallenge with 10(5) PFU of IHD-J-Luc VACV without additional BCV treatment.

183 Challenge with 50,000 pfu of INA-inactivated, mouse-adapted ZEBOV did not caus

184 ranscribed RNA/reaction or approximately 0.1 PFU of infectious virus/reaction) and efficiency (standa

185 eral vaccination of mice with 10(1) or 10(3) PFU of JCV/LACV protected against lethal challenge with

186 (NAb) from TDV were revaccinated with 10(4) PFU of live attenuated DENV-3 vaccine to evaluate memory

187 ld-type) mice were inoculated with 5 x 10(4) PFU of MCMV K181 strain (K181) via the supraciliary rout

188 were inoculated intraperitoneally with 10(7) PFU of parental or recombinant SV40 viruses and were obs

189 infected via the intranasal route with 10(5) PFU of recombinant IHD-J-Luc VACV expressing luciferase.

190 ely resistant to i.c. inoculation with 10(6) PFU of recombinant wild-type MHV-A59 (RA59) virus, these

191 C3H/HeN mice infected with 3 x 10(5) PFU of Rickettsia conorii developed an acute progressive

192 accinated orally with a single dose of 10(8) PFU of rPIV5-RV-G showed a 50% survival rate, which is c

193 mice vaccinated with a single dose of 10(8) PFU of rPIV5-RV-G via the i.m. route showed very robust

194 A single dose of 10(6) PFU of rPIV5-RV-G was sufficient for 100% protection whe

195 STAT2 are highly susceptible to as few as 10 PFU of SFTSV, with animals generally succumbing within 5

196 ue-forming units [PFU] of TDV-1; 6.3 x 10(3) PFU of TDV-2; 3.2 x 10(4) PFU of TDV-3; and 4.0 x 10(5)

197 TDV-1; 6.3 x 10(3) PFU of TDV-2; 3.2 x 10(4) PFU of TDV-3; and 4.0 x 10(5) PFU of TDV-4) in different

198 2; 3.2 x 10(4) PFU of TDV-3; and 4.0 x 10(5) PFU of TDV-4) in different dose schedules (two-dose regi

199 s were trephined and inoculated with 1x10(5) pfu of the Dryvax strain of the vaccinia virus.

200 d lower respiratory tract at a dose of 10(6) PFU of vaccine.

201 hat infection of C57BL/6 mice with 1 x 10(7) PFU of vaccinia virus strain WR results in blepharitis,

202 time of intranasal challenge with 2 x 10(6) PFU of vaccinia virus, resulted in complete protection a

203 ainst viremia when challenged with 1 x 10(5) pfu of virulent RVF virus delivered by a small particle

204 nd human embryonic lung cells exposed to 0.1 pfu of virus per cell was 100-, 10-, and 10-fold higher,

205 t, when guinea pigs are challenged with 1000 pfu of virus.

206 Estimated doses of 10(6.6)-10(8.2) pfu of virus/mL induced major reactions (or "takes") in

207 e L(-/-) PKR(-/-) mice inoculated with 10(8) PFU of VVDeltaE3L, with a distinct pathology.

208 cted mice against lethal challenge with 1000 pfu of ZEBOV.

209 he anti-ZIKV-PSBs can capture as little as 1 PFU of ZIKV in 100 mul of saline, human plasma, or human

210 laterally with 2x10(6) plaque-forming-units (PFU) of adenovirus type 5 (Ad5) after corneal scarificat

211 lation of either 10(3) plaque-forming units (PFU) of DENV-1 or 10(5) PFU of DENV-3.

212 aques were challenged with a high dose (1000 pfu) of MARV-Ang.

213 s receiving no or the lowest dose (1 x 10(5) PFU) of MVA/GM-CSF resisted all 12 challenges.

214 5 x 10(4) or 1 x 10(5) plaque-forming units (pfu) of Rift Valley fever (RVF) MP-12 vaccine by oral, i

215 10(5), 10(6), or 10(7) plaque-forming units (pfu) of the Dryvax strain of the vaccinia virus and scor

216 rs receiving 3 x 10(5) plaque-forming units (pfu) of the recombinant vesicular stomatitis virus-based

217 containing 2.5 x 10(4) plaque-forming units [PFU] of TDV-1; 6.3 x 10(3) PFU of TDV-2; 3.2 x 10(4) PFU

218 ral titers peaked at approximately 1 x 10(6) PFU on day 5 postinfection, and virus had not cleared by

219 At a dose of 2 x 10(2) PFU, one parental virus was absent from each guinea pig

220 icipants received single-injection 3 x 10(5) pfu open-label.

221 3 deployable participants received 3 x 10(5) pfu open-label.

222 igher in the groups that received 20 million PFU or 100 million PFU than in the group that received 3

223 e 130 participants (95%) receiving 3 million PFU or more; rVSV was not detected in saliva or urine.

224 ing sizes to a single injection of 3 x 10(5) pfu or placebo, whereas deployable participants received

225 mized to receive ChimeriVax-WN02 3.7 x 10(5) PFU or placebo.

226 esult in a fatal infection at doses below 10 PFU or with exposure times as short as 2 min.

227 lly with the ISU-1 strain of PRCV (1 x 10(7) PFU) or cell culture medium.

228 before and at the time of intranasal (10(6) PFU) or i.p. (10(7) PFU) challenge with virus resulted i

229 gimens utilizing either high-dose (2 x 10(8) PFU) or low-dose (1 x 10(7) PFU) intramuscular immunizat

230 ants received low-dose rVSV-ZEBOV (3 x 10(5) pfu) or placebo in a double-blind fashion, whereas 13 de

231 units [PFU], 20 million PFU, or 100 million PFU) or placebo.

232 300,000 to 50 million plaque-forming units (PFU) or placebo.

233 llion plaque-forming units [PFU], 20 million PFU, or 100 million PFU) or placebo.

234 ose-dependent decrease in the level of vRNA, PFU, or [RTP]/[GTP] (where RTP is ribavirin-5'-triphosph

235 ng units (PFU), 3.7 x 10(4) PFU, 3.7 x 10(3) PFU, or placebo.

236 33%) pups in the group vaccinated with 10(6) PFU (P < 0.05).

237 h-dose vaccinees receiving at least 1 x10(7) pfu (p<0.0001).

238 bserved across pancreatic cell lines with 10 PFU per cell combined with 1 and 2 mM 5-ALA.

239 o pancreatic lines (mean 57% [SE 10.2] at 10 PFU per cell).

240 but poorly in PML(-/-) cells exposed to 0.1 pfu per cell.

241 amount of infectious virus that we detected (PFU per viral antigen-positive neuron) was similar to th

242 The specific infectivities (PFU per viral genome) of HSV(chol) and HSV(des) were sim

243 ) at 0, 0.1, 1, and 10 plaque-forming units (PFU) per cell for 48 h.

244 atalase, with up to 10 plaque forming units (pfu) per neuron, did not affect cell viability under con

245 e dual-channel PSPWB for S-OIV is 30 PFU/mL (PFU, plaque-forming unit), which was calculated from the

246 y B DNA polymerase from Pyrococcus furiosus (Pfu Pol) contains sensitive determinants of both dNTP bi

247 ics of the enzyme as well as the fidelity of Pfu Pol.

248 PCR amplification using a high-fidelity DNA Pfu polymerase generating a plasmid containing staggered

249 f primer-templates with Pyrococcus furiosus (Pfu) polymerase-DNA complexes containing uracil at +2; m

250 e the three-dimensional structure of PF1378 (Pfu Pop5), one of four protein subunits of archaeal RNas

251 A-inactivated ZEBOV (equivalent to 5 x 10(4) pfu) protected mice against lethal challenge with 1000 p

252 to receive 2 x NYVAC-B followed by 1 x 1010 PFU rAd5 (NYVAC/Ad5hi); 1 x 108 PFU rAd5 followed by 2 x

253 owed by 2 x NYVAC-B (Ad5med/NYVAC); 1 x 1010 PFU rAd5 followed by 2 x NYVAC-B (Ad5hi/NYVAC); or place

254 by 1 x 1010 PFU rAd5 (NYVAC/Ad5hi); 1 x 108 PFU rAd5 followed by 2 x NYVAC-B (Ad5lo/NYVAC); 1 x 109

255 llowed by 2 x NYVAC-B (Ad5lo/NYVAC); 1 x 109 PFU rAd5 followed by 2 x NYVAC-B (Ad5med/NYVAC); 1 x 101

256 5 cells, and the viral genome copy number-to-PFU ratio for VZV in human neurons was 500, compared wit

257 ampered by the fact that the VZV particle-to-PFU ratio has never been determined with precision.

258 4,000- to 20,000-fold increased) particle-to-PFU ratio in vitro than herpes simplex virus (HSV).

259 es, on average, exhibit a higher particle-to-PFU ratio than mosquito cell-derived SINV particles.

260 ay not necessarily have a higher particle-to-PFU ratio than other herpesviruses; instead, the cells p

261 Based on these numbers, the VZV particle:PFU ratio was approximately 40,000:1 for a cell-free ino

262 Particle-to-PFU ratios for E1-139 and E2-196 mutant strains were sim

263 Cell-type-specific particle-to-PFU ratios of HCMV strains that contained different amou

264 ll lines (SINV(C6/36)) exhibited particle-to-PFU ratios similar to those observed for SINV(Heavy).

265 Analyses of particle-to-PFU ratios, relative plaque size, and kinetics of virus

266 ly, producing virions with elevated particle:PFU ratios.

267 d increased physical to infectious particle (PFU) ratios, with additional data suggesting that a late

268 ibitory concentration (FIC indices) based on PFU reduction.

269 cells in vitro due to significantly reduced PFU released per infected cell.

270 aline, 1 x 10(6) (BOOP), or 1 x 10(7) (ARDS) PFU reovirus 1/L, and evaluated at various days postinoc

271 10(2) and 10(2)-10(8) plaque forming units (pfu), respectively.

272 e (LD(5)(0)) values of 0.1 and 0.5 log(1)(0) PFU, respectively, chimeric JCV/LACV is highly attenuate

273 Exposure to 100 PFU resulted in illness and/or lethal infection.

274 nge with doses of r129 virus of >/=5 x 10(6) PFU resulted in levels of maternal viremia, congenital t

275 intranasal inoculation with a low dose (200 PFU) resulted in a 10-fold decrease in vector growth in

276 ep-wise, Mg(2+)-dependent reconstitutions of Pfu RNase P with its catalytic RNA subunit and two inter

277 We investigated Pyrococcus furiosus (Pfu) RNase P, an archaeal RNP that catalyzes tRNA 5' mat

278 Pfu RPP21 in solution consists of an unstructured N-term

279 inal deletion mutant of Pyrococcus furiosus (Pfu) RPP29 that is defective in assembling with its bina

280 xperiments with an enzyme assembled with the Pfu RPR and five protein cofactors (POP5, RPP21, RPP29,

281 nctional when reconstituted with the cognate Pfu RPR.

282 At the inoculation dose of 5.0 x 10(6) PFU, rVSV-HSP70-VP1 stimulated significantly higher T ce

283 At the inoculation dose of 1.0 x 10(6) PFU, rVSV-HSP70-VP1 triggered significantly higher vagin

284 ant animals were vaccinated with 1.0 x 10(4) PFU s.c. at day 42 of gestation, when fetal sensitivity

285 function of the Cst as well as Csa system in Pfu strains harboring a single CRISPR-Cas system.

286 assay was 2.8 x 10(2) plaque-forming units (PFU)/test and 1 x 10(3) PFU/test within 40 minutes for E

287 laque-forming units (PFU)/test and 1 x 10(3) PFU/test within 40 minutes for EBOV-Kikwit and EBOV-Mako

288 that received 20 million PFU or 100 million PFU than in the group that received 3 million PFU, as as

289 es in individuals vaccinated with 20 million PFU than in those vaccinated with 3 million or 100 milli

290 A produced approximately 6- to 13-fold fewer PFU than those from WT virus.

291 e vaccination with 20 million or 100 million PFU than with 3 million PFU, and these correlated strong

292 At inocula above 10(5) pfu the course and severity of corneal disease was not s

293 Infection (with approximately 10(6) PFU, the equivalent of a mosquito bite) of these humaniz

294 ology, and decreased viral titers from 10(6) pfu to undetectable levels.

295 rthermophilic archaeon Pyrococcus furiosus ( Pfu) using conventional and paramagnetic NMR techniques.

296 HPAI H5N1 challenge: a dose as low as 1,000 PFU was sufficient to protect against lethal HPAI H5N1 c

297 e retinas were infected with MCMV (5 x 10(5) PFU/well).

298 a colorimetric substrate was used and 0.1-1 pfu when a chemiluminescent substrate was used.

299 a calculated 50% lethal dose (LD(50)) of 680 PFU, whereas there were no deaths of BALB/c mice at a 10

300 ental HEp-2 and PML(-/-) cells infected at 5 pfu wild-type virus per cell, but poorly in PML(-/-) cel